Lupus Therapeutics Market: Revenue Analysis and Growth Forecasts for Business Expansion 2022-2029
The global lupus therapeutics market is experiencing significant growth due to the rising prevalence of lupus disorders worldwide. Lupus, particularly Systemic Lupus Erythematosus (SLE), affects various organs and has a wide range of clinical symptoms. Recent studies have estimated the incidence and prevalence of SLE in Europe to be between 0.3 to 5.1 per 100,000 per year and 6.5 to 85 per 100,000 population, respectively.
Read More: fairfieldmarketresearch.com/report/lupus-th..
The COVID-19 pandemic has also shed light on the connection between lupus and the virus, potentially contributing to the growth of the lupus therapeutics industry. While the link between COVID-19 and lupus is yet to be fully established, research suggests that COVID-19 could potentially induce systemic lupus erythematosus by creating autoantibodies. There have been reported cases of individuals developing SLE after exposure to COVID-19, further highlighting the need for effective lupus treatments.
The expansion of the lupus therapeutics market is further fueled by an increase in research and development (R&D) activities. The growing number of clinical trials and drug approvals for the treatment of lupus, particularly SLE, provides promising opportunities for market growth. Pharmaceutical companies such as AstraZeneca have recently reported positive results from clinical trials, demonstrating the efficacy of their therapies in reducing SLE symptoms.
North America currently dominates the lupus therapeutics market, driven by the increasing prevalence of lupus in the region. Major key players in the industry are also focusing on introducing novel technologies and treatments, contributing to the market's growth. Investments in advanced healthcare infrastructure and facilities further support the development of the lupus therapeutics market in North America.
However, the Asia-Pacific region is expected to witness significant growth during the forecast period. The region's growing population and rising healthcare expenditure, coupled with increased research and drug development projects, are driving the market's expansion. Biocon Biologics Limited, an Indian biotechnology company, recently initiated a clinical study for a drug targeting Lupus Nephritis, a kidney disease caused by SLE, after receiving approval from the Drugs Controller General of India.
In this competitive landscape, companies are actively introducing new products and engaging in collaborations and partnership agreements to strengthen their market presence. BenevolentAI, a UK-based clinical-stage AI drug discovery business, expanded its collaboration with AstraZeneca for the development of therapeutic medications to treat SLE and heart failure. GlaxoSmithKline plc, a pharmaceutical firm based in the UK, obtained FDA approval for their medicine BENLYSTA (belimumab) for the treatment of SLE-related active lupus nephritis.
Key players in the lupus therapeutics market include Hikma Pharmaceuticals PLC, Lupus Therapeutics, Dr. Reddy's Laboratories Ltd., ADMA Biologics, Inc., AstraZeneca, F.Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Amgen Inc., Novartis AG, Sanofi, UCB S.A., ImmuPharma PLC, Bayer AG, Merck & Co., Inc., Aurinia Pharmaceuticals Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Boehringer Ingelheim International Gmbh.
As the global prevalence of lupus disorders continues to rise, the lupus therapeutics market is poised for significant growth. Investments in R&D, increasing clinical trial approvals, and the introduction of novel treatments are expected to drive advancements in lupus therapeutics, providing new hope for patients worldwide.
Trending Reports: issuu.com/fairfieldmarket/docs/japan_gas_in..
Visit Our Blog: fairfieldmarketresearch.com/blog/the-global..
For further details, please visit fairfieldmarketresearch.com.
Contact
Fairfield Market Research
London, UK
UK +44 (0)20 30025888
USA (Toll-free) +1 (844) 3829746